Dr. Xu has served on ThermoGenesis Holdings’ board of directors since March 2016, and was appointed chairman and interim chief executive officer in November 2016 and CEO in August 2017. He brings over 15 years of leadership experience in the biopharmaceutical industry and has contributed to numerous successful product launches. In 2009, Dr. Xu founded Boyalife Group, a China-based diversified life sciences holding company and is currently the principal shareholder of ThermoGenesis Holdings. Prior to founding Boyalife, Dr. Xu served as a project leader at Pfizer, as a director of research at two publicly-traded companies and as a vice president at Founder Group, a Chinese technology conglomerate focused on information technology, pharmaceuticals, real estate, finance, and commodities trading. Dr. Xu’s expertise spans several diverse therapeutic areas, including arthritis & inflammation, cardiovascular disease, autoimmunity, oncology and diabetes. He has authored over forty publications and has been recognized by numerous professional societies for his contributions to biomedical research. Dr. Xu received his Ph.D. in immunology from Washington University School of Medicine (St. Louis, USA) and an executive MBA from Emory University (Atlanta, USA).
Haihong Zhu, President, joined ThermoGenesis in 2004. Haihong brings over 20 years of technical and sales experience in stem cell research and has contributed significantly to the establishment of ThermoGenesis’ commercial presence in China. She started her career as a Research Scientist at Harvard Medical School Stem Cell Lab and BioTransplant, Inc.
Ms. Zhu graduated from the Shanghai University of Science & Technology with a Bachelor’s in Biology and also studied statistics at Boston University.
Mr. Coelho joined ThermoGenesis Holdings as chief technology officer from SynGen Inc. in July 2017, where he was CTO and co-founder. Mr. Coelho is an engineer and inventor who has been awarded more than 30 U.S. patents related to cell cryopreservation, cryogenic robotics, cell selection, blood protein harvesting, and surgical hemostasis.
Prior to co-founding SynGen, Mr. Coelho founded and ran several companies, including ThermoGenesis Holdings‘ device division, ThermoGenesis Corp., where he also served as chairman and chief executive officer. At ThermoGenesis Holdings, he led the development of many of the company’s key products, including the Thermoline ultra rapid blood plasma freezers and thawers, the CryoSeal automated system for preparing fibrin sealant from a surgical patient’s blood, the BioArchive robotic system for controlled-rate freezing and cryogenically archiving units of hematopoietic stem and progenitor cells (HSPCs) derived from placental/cord blood and the AutoXpress System, which automates the sterile harvesting of HSPCs from cord blood into a 25 ml dual-compartment freezing bag. The BioArchive® and AutoXpress® Systems have defined cGMP standards in cord blood processing and banking worldwide.
In 2002, Mr. Coelho initiated an effort to obtain federal funding sufficient to allow qualified public cord blood banks to build a substantial inventory of ethnically diverse, clinical grade, cord blood stem cell units for all patients in need. Passed unanimously by Congress and signed by President Bush on December 19, 2005, the “Stem Cell Therapeutic and Research Act of 2005” authorized and began financing of a national inventory of 150,000 units of cryopreserved, HLA typed, cord blood stem cells and a website that allowed transplant physicians to choose optimal stem cell units for the treatment of blood cancers such as leukemia, myeloma, and lymphoma; inherited immunodeficiencies and marrow failure disorders and inherited disorders or errors of metabolism. During this last decade, Mr. Coelho has gathered detailed knowledge of the practices of the major public and private cord blood banks in 30 countries and has developed working relationships with many scientists, clinicians and directors associated with these cord blood banks.
As CTO of ThermoGenesis Holdings, Mr. Coelho is leading the development of new products for the clinical and research fields that improve the speed and efficiency of harvesting target cell populations resident within peripheral or placental/cord blood or bone marrow and washing/purifying ex-vivo expanded cell populations derived from those cells.
Mr. Coelho holds a Bachelor’s degree in mechanical engineering from the University of California, Davis.
Jeff Cauble, Chief Financial Officer, joined ThermoGenesis Holdings in 2010. During his time with the company, Mr. Cauble has served in various accounting roles, including Vice President of Finance, Controller and Director of Financial Planning & Analysis. He brings over 20 years of accounting experience in various financial and managerial roles in the biotechnology, medical device and agricultural industries. Mr. Cauble is a Certified Public Accountant and graduate of the University of Idaho, where he obtained a bachelor’s degree with a dual major in accounting and finance.
Mindy Wilke-Douglas, Vice President of Operations, joined ThermoGenesis in 2008. Mindy brings more than 20 years of operational management experience and extensive marketing experience in FDA-regulated biotechnology and medical device industries. Prior to her VP Operations role, she held the position of Director of Customer Operations then Sr. Director of Commercial Operations at ThermoGenesis for 7 years using her worldwide experience in the biotechnology, medical device and cell therapy industries to establish complete commercial programs to nurture end customer and channel partner relationships while also providing leadership to multi-functional project teams.
Prior to joining ThermoGenesis, Mindy held several positions of increasing responsibility at Miltenyi Biotech (US division) where she served for 13 years to develop high-performing cross-functional sales, marketing, technical support and service teams. In addition, she served as an Adjunct Assistant Professor of Biological Sciences and a Research Scientist. Mindy holds a Bachelor’s in Bacteriology and a Master’s in Molecular Biology from the University of California, Davis.